[Malignant lymphoma: update on pathophysiology and management].

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Malignant lymphoma research is evolving, leading to new treatment approaches.
• Understanding the cell of origin (COO) is crucial for diffuse large B cell lymphoma (DLBCL) management.
• The field of tumor immunology is rapidly advancing lymphoma treatment.

Purpose of the Study:

• To highlight novel concepts in malignant lymphoma treatment strategy.
• To emphasize the importance of cell of origin (COO) identification in diffuse large B cell lymphoma (DLBCL).
• To discuss the impact of immunotherapies on lymphoma management.

Main Methods:

• Gene expression profiling for cell of origin (COO) identification in DLBCL.
• Review of recent advancements in immune checkpoint inhibitors.
• Exploration of adoptive cell immunotherapy and other immune therapies.

Main Results:

• Cell of origin (COO) identified via gene expression profiling is a critical indicator for DLBCL.
• Stratification by COO is essential for targeted DLBCL therapies.
• Immunotherapies are transforming malignant lymphoma treatment.

Conclusions:

• Novel treatment strategies for malignant lymphoma are being developed.
• Cell of origin (COO) classification is key for personalized DLBCL treatment.
• The integration of immunotherapy represents a significant shift in lymphoma care.